Healthcare Sector

PFE

Market Tracker

$25.28
+0.07
(+0.28%)
8:00 am
Next Earnings: (est.) 08/01/23 12:00 am
  • PFE (Selected)

    Pfizer Inc.
  • PFEB

    Innovator S&P 500 Power Buffer ETF - February

PFE Support / Resistance Levels

Loading Data..
WhaleStream

15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.

PFE Most Active Options Strike Prices Whale BUY Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.

PFE Most Active Options Strike Prices Whale SALES Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.

PFE Dark Pool and Public Equity Key Price Levels

Loading Data..

Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.

PFE Open Interest Trend

Loading Data..

Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.

PFE Largest 1-Day Open Interest Movements

Expires Type Strike OI Change Percent
04/17/2025 CALL $26.00 43,479 +17,984 +70.54%
04/04/2025 CALL $25.50 11,165 +8,823 +376.73%
04/17/2025 PUT $24.00 19,848 +6,598 +49.80%
04/04/2025 CALL $26.00 18,809 +4,428 +30.79%
04/25/2025 CALL $27.00 11,422 +3,725 +48.40%
01/16/2026 PUT $25.00 60,629 +3,038 +5.28%
04/17/2025 PUT $23.00 13,993 -207 -1.46%
05/16/2025 CALL $29.00 25,668 -277 -1.07%
04/17/2025 PUT $25.00 44,078 -303 -0.68%
06/20/2025 PUT $25.00 60,823 -421 -0.69%
06/18/2026 PUT $32.00 3,769 -5,093 -57.47%
04/17/2025 CALL $29.00 28,837 -7,936 -21.58%

Contracts with largest changes in open interest from the previous trading day to the current/most recent.

PFE Major Holders

Name Pct Held Shares Total
Vanguard Total Stock Market Index Fund 3.02% 170.64M 6.14B
Vanguard 500 Index Fund 2.30% 129.76M 4.67B
Washington Mutual Investors Fund 1.42% 80.41M 2.89B
Fidelity 500 Index Fund 1.09% 61.54M 2.21B
SPDR S&P 500 ETF Trust 1.08% 60.77M 2.19B
American Balanced Fund 1.00% 56.61M 2.04B
Income Fund of America Inc 0.93% 52.68M 1.9B
iShares Core S&P 500 ETF 0.89% 50.1M 1.8B
Vanguard Index-Value Index Fund 0.86% 48.51M 1.75B
Vanguard Specialized-Health Care Fund 0.86% 48.32M 1.74B

PFE News

  • Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine

    03/31 08:56 am

    Benzinga

    Read more
  • Why Pfizer Is My Largest Healthcare Position

    03/27 06:45 am

    The Motley Fool

    Read more
  • Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

    03/22 06:44 am

    The Motley Fool

    Read more
  • Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed

    03/21 12:31 pm

    Benzinga

    Read more
  • 3 Reasons Pfizer Stock Could Be a Steal of a Deal in 2025

    03/20 09:45 am

    The Motley Fool

    Read more
  • 1 Reliable Dividend Stock You Can Buy Now and Hold at Least a Decade

    03/20 06:17 am

    The Motley Fool

    Read more
  • Pfizer Offloads Its Last 7% Stake In Consumer Health Haleon For Over $3 Billion

    03/19 10:40 am

    Benzinga

    Read more
  • 5 Reasons the Schwab U.S. Dividend Equity ETF Is a Long-Term Buy for 2030 and Beyond

    03/17 07:45 am

    The Motley Fool

    Read more
  • Down 93%, Is It Finally Time to Buy Moderna?

    03/15 04:38 am

    The Motley Fool

    Read more
  • Pfizer's Direct-To-Consumer Model Faces Scrutiny From US Senators (UPDATED)

    03/13 02:23 pm

    Benzinga

    Read more
  • This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year

    03/13 07:30 am

    The Motley Fool

    Read more
  • GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study

    03/12 05:24 pm

    Benzinga

    Read more
  • Bispecific Antibody Market Opportunity, Drug Dosage, Patent, Price, Sales & Clinical Trials Insight 2030: New Report Highlights 600+ Bispecific Antibodies in Clinical Trials Worldwide

    03/12 08:48 am

    GlobeNewswire Inc.

    Read more
  • BioNTech Surpasses Q4 Revenue Estimates

    03/10 08:42 am

    The Motley Fool

    Read more
  • Global Prostate Cancer Market to Reach USD 29.2 Billion by 2035, Driven by Aging Population and Awareness | Future Market Insights, Inc.

    03/09 08:30 pm

    GlobeNewswire Inc.

    Read more
  • 3 Top Dividend Stocks to Buy in March

    03/08 09:30 am

    The Motley Fool

    Read more
  • BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight

    03/04 02:00 pm

    GlobeNewswire Inc.

    Read more
  • 1 Stock Down 43% That Looks Too Cheap to Ignore

    03/04 10:45 am

    The Motley Fool

    Read more
  • JAK Inhibitors Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight

    03/03 02:00 pm

    GlobeNewswire Inc.

    Read more
  • 2 Top Stocks Beaten Down Near 52-Week Lows That Look Like Bargains Now

    03/02 05:21 am

    The Motley Fool

    Read more
  • 3 Dividend Stocks That Are No-Brainer Buys Right Now

    03/01 06:51 am

    The Motley Fool

    Read more
  • OPZELURA Continues to Revolutionize Dermatology Market with Strong Market Uptake | DelveInsight

    02/28 02:00 pm

    GlobeNewswire Inc.

    Read more
  • Derm-Biome’s DB-007-5 is highly effective at treating atopic dermatitis and reducing itch in preclinical study, outperforming the current leading topical AD drug

    02/26 11:00 am

    GlobeNewswire Inc.

    Read more
  • TALTZ’s Rapid Market Ascent Reflects its Unparalleled Ability to Transform the Treatment Landscape for Autoimmune Diseases | DelveInsight

    02/24 02:00 pm

    GlobeNewswire Inc.

    Read more
  • CD47 Antigen Inhibitors Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight

    02/24 02:00 pm

    GlobeNewswire Inc.

    Read more
  • Questex’s Fierce Pharma Unveils the Conference Program for the Inaugural Fierce Pharma Engage, Over 100 Speakers Confirmed to Deliver Unparalleled Education

    02/24 11:00 am

    GlobeNewswire Inc.

    Read more
  • Prediction: These Could Be the Best-Performing Value Stocks Through 2030

    02/23 04:26 pm

    The Motley Fool

    Read more
  • 3 Ultra-High-Yield Dividend Stocks You Can Buy and Hold Forever

    02/23 05:53 am

    The Motley Fool

    Read more
  • Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight

    02/21 02:00 pm

    GlobeNewswire Inc.

    Read more
  • Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight

    02/21 02:00 pm

    GlobeNewswire Inc.

    Read more
  • Hyperlipidemia Drugs Market Size to Promote USD 31.49 Bn by 2034

    02/21 11:00 am

    GlobeNewswire Inc.

    Read more
  • 2 No-Brainer Healthcare Stocks to Buy With $500 Right Now

    02/21 06:50 am

    The Motley Fool

    Read more
  • Antibody-Drug Conjugates Market to Witness Rapid Growth Across 7MM During the Study Period (2020–2034) as New Innovations Drive Therapy Advancements | DelveInsight

    02/20 02:00 pm

    GlobeNewswire Inc.

    Read more
  • The Smartest Dividend Stocks to Buy With $1,000 Right Now

    02/20 05:45 am

    The Motley Fool

    Read more
  • Want Decades of Passive Income? Buy This ETF and Hold It Forever.

    02/18 07:15 am

    The Motley Fool

    Read more
  • 3 Things You Need to Know If You Buy Pfizer Today

    02/18 05:35 am

    The Motley Fool

    Read more
  • Pfizer's Talzenna/Xtandi Combo Improves Survival Outcomes In Metastatic Castration-Resistant Prostate Cancer

    02/14 12:48 pm

    Benzinga

    Read more
  • Respiratory Syncytial Virus Therapeutics Market to Hit USD 4.64 Billion by 2032, Growing at a 14.5% CAGR – SNS Insider

    02/13 10:00 am

    GlobeNewswire Inc.

    Read more
  • 3 Brand-Name, Ultra-High-Yield Dividend Stocks Patient Investors Can Confidently Buy With $300 Right Now

    02/13 06:06 am

    The Motley Fool

    Read more
  • 3 Dividend Stocks to Double Up on Right Now

    02/09 06:43 am

    The Motley Fool

    Read more
  • Paresthesia Treatment Market Outlook: USD 8.0 Billion by 2034, Growing with an Aging Population and Rising Healthcare Expenditures | Analysis by TMR

    02/07 12:39 pm

    GlobeNewswire Inc.

    Read more
  • Respiratory Disease Vaccines Market Research Report 2025: Analysis and Forecast (2020-2030) Featuring GSK, Johnson & Johnson Services, Pfizer, Sanofi, Serum Institute of India, SINOVAC Biotech & More

    02/06 05:51 am

    GlobeNewswire Inc.

    Read more
  • Aplastic Anemia Global Clinical Trials Review 2024 | Now Available

    02/04 12:00 pm

    GlobeNewswire Inc.

    Read more
  • 2 Ultra-High-Yield Dividend Stocks That Are No-Brainer Buys in February

    02/04 06:06 am

    The Motley Fool

    Read more
  • Pfizer Trial For Colorectal Cancer Treatment Shows Improved Survival In Late-Stage Study

    02/03 11:34 am

    Benzinga

    Read more
  • Recombinant Chemicals Market to Reach US$ 6.7 Bn by 2034, Driven by Rising Demand for Protein-Based Vaccines & Genetic Disorder Treatments – TMR Analysis

    01/31 10:00 am

    GlobeNewswire Inc.

    Read more
  • BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight

    01/29 02:00 pm

    GlobeNewswire Inc.

    Read more
  • I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.

    01/28 07:15 am

    The Motley Fool

    Read more
👀

Follow the Whales in real-time.

🎁

Take 50% OFF With Code: